Grantham Mayo Van Otterloo & Co. LLC Has $34.27 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Grantham Mayo Van Otterloo & Co. LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 65,283 shares of the biopharmaceutical company’s stock after selling 18,047 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC owned approximately 0.06% of Regeneron Pharmaceuticals worth $34,274,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Cove Private Wealth LLC grew its stake in Regeneron Pharmaceuticals by 4.5% in the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 20 shares during the last quarter. Marino Stram & Associates LLC raised its stake in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 20 shares during the last quarter. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the last quarter. CX Institutional increased its holdings in shares of Regeneron Pharmaceuticals by 7.9% during the 2nd quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 22 shares during the period. Finally, Redwood Wealth Management Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 23 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on REGN shares. Jefferies Financial Group boosted their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday. Finally, Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $757.91.

Insider Buying and Selling

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ REGN opened at $784.61 on Friday. The company’s 50 day simple moving average is $631.01 and its 200 day simple moving average is $582.01. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $800.99. The firm has a market capitalization of $82.46 billion, a P/E ratio of 18.79, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the business posted $12.46 EPS. The firm’s quarterly revenue was up .9% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.